Class: Other Nonsteroidal Anti-inflammatory Agents
VA Class: CN103
Chemical Name: (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid compd. with 2-Amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
Molecular Formula: C15H13O3•C4H11NO3
CAS Number: 74103-07-4
Brands: Sprix
Warning
- Appropriate Use
Parenteral and oral ketorolac indicated for short-term (≤5 days) management of moderately severe acute pain that requires analgesia at opiate level. Oral ketorolac indicated only for continuation therapy and only if necessary; do not exceed 5 days of total parenteral and oral therapy. Not indicated for pediatric use or for use in minor or chronic painful conditions.
Increasing the dose beyond the recommended dose will not result in improved efficacy and increases the risk of serious adverse effects.
- GI Effects
Can cause peptic ulcers, GI bleeding, and/or perforation,. Contraindicated in patients with active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic ulcer disease or GI bleeding.
Serious GI events can be fatal and can occur at any time and may not be preceded by warning signs and symptoms. Geriatric individuals and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. (See GI Effects under Cautions.)
- Cardiovascular Risk
Increased risk of serious (sometimes fatal) cardiovascular thrombotic events (e.g., MI, stroke). Risk may occur early in treatment and may increase with duration of use. (See Cardiovascular Thrombotic Effects under Cautions.)
Contraindicated in the setting of CABG surgery.
- Renal Effects
Contraindicated in patients with advanced renal impairment and those at risk of renal failure because of volume depletion.
- Hematologic Effects
